Language:

Oxidative Phosphorylation as an Emerging Target in Cancer Therapy

Clinical cancer research, 2018-06, Vol.24 (11), p.2482-2490 [Peer Reviewed Journal]

2018 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Jun 1, 2018 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-17-3070 ;PMID: 29420223

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Oxidative Phosphorylation as an Emerging Target in Cancer Therapy
Author: Ashton, Thomas M ; McKenna, W Gillies ; Kunz-Schughart, Leoni A ; Higgins, Geoff S
Subjects: Adenocarcinoma ; Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Arsenic ; Arsenic trioxide ; Atovaquone ; Biomarkers ; Cancer ; Endometrium ; Energy Metabolism - drug effects ; Glycolysis ; Humans ; Hypoxia ; Inhibitors ; Kinases ; Leukemia ; Lymphoma ; Melanoma ; Metabolic Networks and Pathways ; Metabolism ; Metformin ; Mitochondria - drug effects ; Mitochondria - genetics ; Mitochondria - metabolism ; Molecular Targeted Therapy - methods ; Neoplasms - etiology ; Neoplasms - metabolism ; Neoplasms - therapy ; Oxidative phosphorylation ; Oxidative Phosphorylation - drug effects ; Pancreas ; Phosphorylation
Is Part Of: Clinical cancer research, 2018-06, Vol.24 (11), p.2482-2490
Description: Cancer cells have upregulated glycolysis compared with normal cells, which has led many to the assumption that oxidative phosphorylation (OXPHOS) is downregulated in all cancers. However, recent studies have shown that OXPHOS can be also upregulated in certain cancers, including leukemias, lymphomas, pancreatic ductal adenocarcinoma, high OXPHOS subtype melanoma, and endometrial carcinoma, and that this can occur even in the face of active glycolysis. OXPHOS inhibitors could therefore be used to target cancer subtypes in which OXPHOS is upregulated and to alleviate therapeutically adverse tumor hypoxia. Several drugs including metformin, atovaquone, and arsenic trioxide are used clinically for non-oncologic indications, but emerging data demonstrate their potential use as OXPHOS inhibitors. We highlight novel applications of OXPHOS inhibitors with a suitable therapeutic index to target cancer cell metabolism. .
Publisher: United States: American Association for Cancer Research Inc
Language: English
Identifier: ISSN: 1078-0432
EISSN: 1557-3265
DOI: 10.1158/1078-0432.ccr-17-3070
PMID: 29420223
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Oxidative Phosphorylation as an Emerging Target in Cancer Therapy

2018 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Jun 1, 2018 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-17-3070 ;PMID: 29420223

Searching Remote Databases, Please Wait